Pneumococcal surface proteins
AssigneesThe University of Tokyo, Hanavax Inc.
InventorsYoshikazu Yuki, Rika Nakahashi, Hiroshi Kiyono
Life of this patent
Estimating the term…
Abstract
The present invention provides D39-derived mutant PspA that does not undergo deamination and maintains stability as a molecule even around neutral pH range. Specifically, the present invention relates to a protein of the following (a) or (b): (a) a protein comprising the amino acid sequence as set forth in SEQ ID NO: 2 and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein; or (b) a protein being a part of the amino acid sequence as set forth in SEQ ID NO: 2, wherein aspartic acid at position 254 is comprised in the part, and having pneumococcal vaccine antigenic activity, and a protein substantially identical to the protein.
Claims9
A protein comprising:
- (a) an amino acid sequence as set forth in SEQ ID NO:
- 3, or
- (b) an amino acid sequence having 90% or more sequence identity to SEQ ID NO:
- 3, wherein the aspartic acid at position 254 of SEQ ID NO:
- 3 is retained,
- wherein the protein has pneumococcal vaccine antigenic activity.
Dependencies are inferred from the claim text.